AKKO, Israel, March 14, 2017 -- Cheetah Solver for Autodesk® AutoCAD® is a plugin that replaces the built-in parametric of AutoCAD with the enhanced parametric technology developed by Cloud Invent to enable much more efficient sketching, design modification and motion simulation. Cheetah Solver is a robust and powerful parametric tool that boosts user productivity and lowers engineering costs and errors.
Cloud Invent is moving Cheetah Solver to a full commercial release after a successful beta test, which lasted for six months and included 1500 users from 20 countries.
“We built a world-class product that revolutionizes the way users work with AutoCAD,” said Nick Sidorenko, founder and Chief Executive Officer for Cloud Invent. “We are extremely excited to have reached to the point of our commercial launch. Rest assured we will continue improving Cheetah Solver bringing new functions and benefits to AutoCAD users.”
Cheetah Solver is available for download on Autodesk Apps Store and Cloud Invent website.
About Cloud Invent
Cloud Invent develops innovative parametric solutions for the Computer Aided Design industry. Its ground-breaking parametric technology changes the way users work with CAD software enabling them to use the full power of parametric modeling for much more efficient sketching, design modification, and motion simulation. Most recently, Cloud Invent has designed and delivered Cheetah Solver for AutoCAD plugin that replaces the built-in geometric constraints solver with the enhanced parametric technology.
Contact Nick Sidorenko CEO, Cloud Invent +972 (506) 926770 [email protected]


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 



